


## Vascular Flow Technologies partners with Biovic

25 November 2017 | News

**This strategic partnership will see VFT's Spiral Laminar Flow (SLF(TM)) technology used to enhance Biovic's existing AVATAR(R) ePTFE Vascular Graft**



Medical Device company, Vascular Flow Technologies has announced the successful conclusion of a strategic intellectual property out-licencing agreement with Biovic.

Vascular Flow Technologies is the medical device company who developed the proprietary Spiral Laminar Flow (SLF(TM)) technology to re-establish natural blood flow for enhanced patient outcomes.

Biovic are a Malaysian based high tech biomedical company focussed on meeting the needs of patients in developing medical communities with high quality, transformational products.

This strategic partnership will see VFT's Spiral Laminar Flow (SLF(TM)) technology used to enhance Biovic's existing AVATAR(R) ePTFE Vascular Graft. VFT's SLF(TM) technology is a unique and IP protected design which eliminates the turbulent blood flow seen in diseased vessels and standard prosthetic vascular grafts. By reintroducing the normal pattern of blood flow through the vessel, graft failure and complications for the patient are significantly reduced.

The technology is built on an extensive base of evidence produced using CFD (models of fluid flow created with numerical analysis) and FEA (virtual modelling to problem solve potential stresses on vessel walls).

Craig Dunlop, General Manager of Vascular Flow Technologies, commented: "This is a very exciting opportunity for VFT and Biovic. Combining the superior clinical performance of VFT's SLF(TM) technology with a high performance ePTFE graft, will disrupt the existing market with an enhanced ePTFE Vascular graft with unique new features and patient benefits."

VFT and Biovic will collaborate closely over the coming months to bring the Avatar SLF (TM) graft to the market by Q2 2018.

This agreement underpins and validates VFT's revised business model of collaborative SLF(TM) product development across multiple treatment areas including Peripheral Stents, Hybrid Stent Grafts and Haemodialysis Catheters. VFT continues to work with the key players in these sectors to apply SLF technology to existing products thereby addressing unmet patient and

clinical needs. VFT's diverse new product pipeline is supported by 18 strong patent families.